Consensus Tempest Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.25 ^USD	-6.34%		-8.19%	-26.14%

Apr. 09	Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	CI
Apr. 04	Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	CI

a8f4.Q6yaFEPinoiF0OTsc1GjTQyZx3YRLdc8IC2-sebnOhs.M5XQORym87vAiKKUSw7OBVXLokB0foh_SXX40LauXS4hwa57DLr_8e28gw~185e75528e82b4ec1b152d94fc40140e

Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	Mar. 14	MT
HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	23-10-11	MT
Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	23-03-23	MT
Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target	22-09-15	MT
HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating	22-05-13	MT
Piper Sandler Adjusts Price Target on Tempest Therapeutics to $20 From $23, Reiterates Overweight Rating	22-04-28	MT
TEMPEST THERAPEUTICS : William Blair Initiates Tempest Therapeutics at Outperform Rating	21-10-21	MT
TEMPEST THERAPEUTICS : HC Wainwright Starts Tempest Therapeutics at Buy With $51 Price Target	21-07-13	MT
TEMPEST THERAPEUTICS : Piper Sandler Starts Tempest Therapeutics at Overweight With $23 Price Target	21-07-06	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.25 USD

Average target price

18.6 USD

Spread / Average Target

+472.31%

High Price Target

47 USD

Spread / Highest target

+1,346.15%

Low Price Target

8 USD

Spread / Lowest Target

+146.15%